Bad blood (Record no. 7612)

MARC details
000 -LEADER
fixed length control field 01970nam a2200169Ia 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250117103904.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250117s9999 xx 000 0 und d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 97815909868087
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 338.768CAR
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Carreyrou, John.
245 #0 - TITLE STATEMENT
Title Bad blood
Remainder of title secrets and lies in a Silicon Valley Startup
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. New York
Name of publisher, distributor, etc. Vintage Books
Date of publication, distribution, etc. 2020
300 ## - PHYSICAL DESCRIPTION
Extent x, 341p., 8 unnumbered pages of plates : ill. ; 21 cm
500 ## - GENERAL NOTE
General note Includes bibliographical references (pages 307-326) and index.
520 ## - SUMMARY, ETC.
Summary, etc. "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at
-- billion, putting Holmes's worth at an estimated
-- .7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Theranos (Firm)--History.
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Total checkouts Full call number Barcode Date last seen Price effective from Koha item type
        UONGOZI Institute Resources Centre - Dodoma UONGOZI Institute Resources Centre - Dodoma Philosophy 01/17/2025   338.768CAR URD000077 01/31/2025 01/17/2025 Book